Welcome to our dedicated page for Anixa Biosciences news (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences stock.
Anixa Biosciences, Inc. reports biotechnology developments tied to the treatment and prevention of cancer. The company's recurring news centers on its investigational breast cancer vaccine, developed with Cleveland Clinic and based on an α-lactalbumin immune-targeting approach, and liraltagene autoleucel, or lira-cel, an FSHR-targeted CAR-T therapy for recurrent ovarian cancer.
Company updates also cover clinical-trial observations, scientific conference presentations, intellectual-property protection for vaccine technology, manufacturing arrangements for clinical materials, and management presentations describing Anixa's oncology pipeline and business model.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced a technical error in its website that led to an unrelated poster presentation being displayed on the Corporate Presentations page. The company clarified that the correct presentation of its breast cancer vaccine clinical trial from the 2023 AACR Annual Meeting can be found on the Events page of its website. Anixa focuses on cancer treatment and prevention, collaborating with renowned institutions like Moffitt Cancer Center and Cleveland Clinic for its innovative therapies, including CAR-T technology and vaccines targeting triple negative breast cancer and ovarian cancer.